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Abstract
Background: Synovial sarcoma (SS) is one of the most aggressive soft-tissue sarcomas and is noted for late local
recurrence and metastasis. It is of uncertain histological origin and exhibits a biphasic histopathological form
involving both the mesenchyme and epithelium. Thus, its diagnosis and therapy remain a huge challenge for
clinicians and pathologists. This study aimed to determine whether differential morphological-associated genomic
changes could aid in ascertaining the histogenesis of SS and to determine whether these sarcomas showed some
specific mutated genes between epithelial and spindle cells that would promote tumor invasion and metastasis.
Methods: We conducted a comprehensive genomic analysis of mesenchymal and epithelial components in 12
formalin-fixed paraffin-embedded biphasic SS samples using the Illumina human exon microarray. Exome capture
sequencing was performed to validate the single nucleotide polymorphism (SNP)-chip data, and de novo data were
generated using a whole-exome chip with the Illumina exon microarray. Fisher’s exact test based on PLINK analysis
of the SNP-chip data.
Results: Here, the SNP-chip data showed that 336 SNPs had association P-values of less than 0.05 by chi-square
test. We identified 23 significantly mutated genes between epithelial and spindle cell regions of SSs. Fifteen gene
mutations were specific for the spindle cell component (65.2 %) and eight for the epithelial cell component
(34.8 %). Most of these genes have not been previously reported in SS, and neuroguidin (NGDN), RAS protein
activator like 3 (RASAL3), KLHL34 and MUM1L1 have not previously been linked to cancer; only one gene (EP300) has
been reported in SS. Genomic analyses suggested that the differential SNPs in genes used for functional
enrichment are mainly related to the inflammatory response pathway, adhesion, ECM–receptor interactions, TGF-β
signaling, JAK–STAT signaling, phenylalanine metabolism, the intrinsic pathway and formation of fibrin.
Conclusions: This study investigated novel biological markers and tumorigenic pathways that would greatly
improve therapeutic strategies for SS. The identified pathways may be closely correlated with the pathogenic
mechanisms underlying SS, and SS development is associated with morphological features.
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Background
Synovial sarcoma (SS) is a highly aggressive mesenchymal
tumor with typical dual epithelial and mesenchymal differ-
entiation [1]. It affects pediatric, adolescent, and adult
populations and comprises approximately 10 % of all soft-
tissue sarcomas; the age-standardized incidence rate per
million individuals ranges from 0.5 to 1.3 [2]. SS has a wide
spectrum that includes two main variants: monophasic fi-
brous SS, the most common variant and biphasic SS (BSS),
which displays glandular epithelial differentiation architec-
ture in a background of spindle cells. SS likely originates
from undifferentiated mesenchymal tissue with variable
epithelial differentiation and highly specific chromosomal
translocation in more than 95 % of cases [3]. However, the
molecular mechanisms underlying tumorigenesis and dual
differentiation have remained elusive.
Much of the available literature on SS comprises case
reports. Research on the pathogenesis of SS is mainly fo-
cused on the relationship between fusion genes and
diagnosis or prognosis. However, the cell-of-origin, dual
differentiation of SS and the histological transitional re-
lationships between epithelial and mesenchymal differ-
entiation are unclear.
Recent advances in genomic technologies have offered a
great opportunity for identifying the complete biological
characteristics of neoplastic tissues, resulting in improved
diagnosis, treatment selection, rational classification
based on molecular carcinogenesis, and identification
of therapeutic targets. Genome-wide single nucleotide
polymorphism (SNP) analysis is a powerful approach
that allows for the investigation of genomes and transcrip-
tomes using limited sample material, and identification of
disease-causing genes; other advantages include its abun-
dance in the human genome and ease of high-throughput
typing therapy [4]. Thus, these methods have great poten-
tial for guiding therapy.
Because of the relative rarity of SS and the poor prog-
nosis, it is not easy to collect an adequate number of SS
samples for a genome-wide association study. However,
new cost-effective technologies such as microarray SNP-
chip typing and whole exome sequencing have allowed
us to identify candidate genes, mutations and potential
targets for further study and validation [5]. Here, we
integrated the resulting data for 319 target genes with
those from existing open-source resources with the
following aims: detection of somatic variants between
the epithelial and mesenchymal components in SS by
genome-wide SNP analysis; linkage of target genes
with additional biologically significant pathways and
gene sets; and to provide insights into our previous
mechanistic studies, thereby providing the basis for fur-
ther experiments for characterizing the genetic factors
that are involved in pathogenesis and that could aid in fu-
ture targeted therapies for SS.
Methods
Patients and tissue specimens
Twelve formalin-fixed, paraffin-embedded (FFPE) BSS
samples that were confirmed to have a fusion gene and
obtained from patients treated at the Department of
Pathology, First Affiliated Hospital, Shihezi University,
School of Medicine, between 1980 and 2011, were in-
cluded in this series. Clinical and demographic data were
obtained from the medical charts. The diagnosis of SS
was confirmed by histological and immunohistochemical
analyses and the presence of a fusion gene was detected
by One Step RT-PCR (QIAGEN, Venlo, The Netherlands).
The characteristics of the 12 BSS patients enrolled in this
study are shown in Table 1. Clinical staging was per-
formed according to the National Comprehensive Cancer
Network 2012 guidelines for soft-tissue tumors. Follow-up
surveys were conducted.
Table 1 Clinical Description of BSSs Patients for Genome-Wide SNP
Case sex/age Location Size (cm) FNCLCC pTNM Metastases Status at last follow-up Fusion gene
1 F/55 left ilium 5 3 IV lung DOD SYT-SSX1
2 F/22 Left heel 3 3 IIA NA SYT-SSX1
3 M/40 Right groin 22 2 IV liver AWD 9 months after presentation SYT-SSX2
4 F/10 Right elbow 5 3 IV Bone marrow cavity DOD SYT-SSX1
5 M/64 Left hip 11.5 3 IV lung DOD SYT-SSX1
6 M/32 Oral 3 3 I lung DOD SYT-SSX1
7 F/37 Right tibia 6; 5 3 III DOD SYT-SSX1
8 F/21 Right thigh 7.5 3 I AWD 27 months after presentation SYT-SSX1
9 M/55 Right foot 5.2 3 I lung DOD SYT-SSX1
10 M/47 Left leg 5 3 IV lung DOD SYT-SSX2
11 M/39 Left hand and forearm 6 3 IV Bone DOD NA
12 M/52 Right kidney 5 3 III AWD 23 months after presentation SYT-SSX2
F female, M male, NA not available, BSS biphasic synovial sarcoma, AWD alive with disease, DOD died of disease, NA not available
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Written informed consent was obtained from all pa-
tients regarding the use of the collected samples in re-
search studies. The patient records and information
were anonymized and de-identified before analysis. Hu-
man subjects in this study provided informed consent
for use of their tissues for research purposes following
procedures approved by the Clinical Research Ethics
board of the First Affiliated Hospital, Shihezi University
School of Medicine.
Tissue preparation and microscopic separation of the
epithelial and spindle cell components of BSSs
Laser capture microdissection (LCM) and tissue chips
were used for separation of the epithelial and spindle cell
components in12 cases of biphasic SS. For LCM, paraf-
fin sections were deparaffinized in xylene, rehydrated
through a graded alcohol series to distilled water, and
then stained with hematoxylin. Epithelial cells and
spindle cells were isolated from the slides using LCM
(PixCell II Laser Capture Microdissection System;
Arcturus Engineering Inc. Mountain View, CA, USA).
The cells were captured using a 30-μm pulse to fo-
cally melt a thermoplastic membrane attached to a
transparent flat cap (PixCell II Laser Capture Micro-
dissection System). After LCM, the cap containing the
captured tissue was placed on a 0.5-mL standard
Eppendorf microfuge tube.
For tissue chip separation, regions of the epithelial cell
and spindle cell components in the paraffin block were
selected by comparing the results of hematoxylin eosin
staining. A hollow needle (diameter, 1.0 mm) was used
to puncture the selected area to a new small wax block.
DNA extraction and SNP array
Genomic DNA was isolated from the FFPE tumor sam-
ples using the QIAamp DNA Micro Kit (Qiagen Inc.,
Valencia, CA, USA) in accordance with the manufac-
turer’s instructions. The lowest amount of genomic
DNA for which the genomic SNP chip analysis was suc-
cessful was 1 μg. The DNA was extracted from 24 FFPE
tissue samples (12 patients), with quality metrics of
A260/280 = 1.7–2.0 and A260/230 > 1.6. DNA targets
from patients were prepared and hybridized to Infinium
HD Assay Super chips following the manufacturer’s rec-
ommendations. Quality analysis was performed by
importing the CEL files into Illumina Human Exome-
12v1.1 according to the “Quality Control Assessment in
Genotyping Console”. Association analysis was performed
for control versus case with the PLINK (http://pngu.mgh.
harvard.edu/~purcell/plink) software, using the Fisher’s
exact test, chi-square test and estimated odds ratio.
Pearson chi-square values and P-values (chi-square
and Fisher’s exact test) were calculated using Haploview
4.2. PLINK data.
Illumina exon microarray detection
A custom microarray with exon level resolution was de-
veloped to identify gross deletions and duplications. Study
samples were processed using Illumina Human Exome-
12v1.1 (Beijing Compass Biological Technology Co. Ltd;
http://www.kangpusen.com/index.html). The microarray
contains approximately 60,000 integrated oligonucleotide
probes that have been annotated against the human gen-
ome assembly build. The probes’ density was increased in
the exons and 300 bp flanking intronic sequence. In
addition, probes were placed at every 2.5 Kb of the
intronic sequence and heavily tiled in promoter regions.
After validation runs, only probes with optimal perform-
ance were selected for the final array design.
Briefly, the standard DNA plate was prepared first,
and then the standard QNT plate with diluted Pico-
Green and the sample QNT plate with PicoGreen and
DNA were prepared. Subsequently, the DNA samples
were shifted to the MSA1 plate. The samples were dena-
tured and neutralized, and then prepared for amplifica-
tion by overnight incubation. The next day, the DNA
was enzymatically fragmented using end-point fragmen-
tation to avoid over-fragmentation. Then, the DNA sam-
ples were treated with 2-propanol and PM1 to
precipitate MSA1, and the precipitated DNA was resus-
pended using RA1. Next, the fragmented resuspended
DNA samples were dispensed on BeadChips. The Bead-
Chips were incubated in the Illumina hybridization oven
to hybridize the samples onto the BeadChips. The incu-
bation time was appoximately16–24 h. The next day, the
BeadChips were prepared for the staining process, and
the unhybridized and non-specifically hybridized DNA
was washed off. Labeled nucleotides were added to ex-
tend the primers hybridized to the DNA. The primers
were stained, the flow-through chambers were disas-
sembled, and the BeadChips were coated for protection.
The iScan System and the Illumina BeadArray Reader
were using by the Illumina GenomeStudio Genotyping
Module. There are eight categories of internal control in
an exon array Illumina SNP microarray experiment for
each sample: staining, extension, hybridization, strin-
gency, target removal, restoration, non-specific binding
and non-polymorphic controls. Quality analysis of the
Illumina HumanExome-12v1.1 report samples showed
that the call rate was 0.7526.
Functional annotation
WebGestalt (WEB-based GEne SeT AnaLysis Toolkit;
http://bioinfo.vanderbilt.edu/webgestalt) [6], which in-
volves the KEGG database, Pathway Commons and
WikiPathways Analysis, was used for functional
enrichment analysis and hierarchical clustering of
SNPs detected by SNP Chip. P-values were calculated
at medium classification stringency using a modified
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Fisher’s exact test (EASE score), and terms with
P-values of < 0.05 were considered significantly enriched.
The enriched protein interaction network modules





The study cohort included 12 patients with definite epi-
thelial and spindle cells in BSSs. The patients were pre-
dominantly male (seven [58.3 %] versus five female
patients [41.7 %]), with the age at diagnosis ranging from
10 months to 64 years (mean age, 39 years). The tumors
had a wide anatomical distribution; however, most arose
in the upper and lower limbs (6, 38 %), and the head
and neck region (5, 31 %). A total of five tumors (25 %)
occurred in the retroperitoneum, hip, spinal canal, lung
and thoracic wall. Clinical follow-up was available for
11 cases. The mortality rate was very high, that is,
63.6 % (7 of 11 patients) patients died of the disease or of
subsequent metastasis. Some of the surviving patients ex-
perienced local recurrence or liver and lung metastases.
The data are listed in Table 1.
Exome-chip analysis
We performed exome capture sequencing to validate the
SNP chip data and to identify SNPs not present on the
array. Approximately 249,101 single-nucleotide variants
and small insertion and deletion changes were discov-
ered for the epithelial and spindle cells components in
the genomes of the 12 patients on comparison with the
current reference haploid human genome sequence
(Fig. 1a). The Fisher’s exact test based on PLINK analysis
of the SNP-chip data showed that 336 SNPs had associ-
ation P-values of less than 0.05 (P < 0.05, chi square test)
Additional file 1. Because our studies were limited by
the small number of patients with BSSs, we set an initial
threshold for genome-wide significance of less than 10–
3 by the chi-square test and further analyzed variants
meeting this criterion. Analysis with the PLINK and
Haploview software showed that a total of 23 SNPs in 23
genes (CTH, RBM44, LARS, HNRNPA, ADAMTS2,
F13A, TNXB, ADAP1, PIK3CG, GCN1L1, NGDN,
AHNAK2, ACAN, PRR14, DSEL, ETV2, DERL3, CELSR1
and BCORL1) had association P-values of less than 10–3
(Fig. 1b). All these SNPs were located in exonic regions.
Mutations in 15 genes were specific for the spindle cell
component (15/23, 65.2 %) (CTH, RBM44, LARS,
HNRNPA, F13A, PIK3CG, GCN1L1, NGDN, AHNAK2,
PRR14, RASAL3, DERL3, CELSR1, KLHL34 and EP300),
and those in eight genes were specific for the epithelial cell
component (8/23, 34.8 %) (ADAMTS2, TNXB, ADAP1,
ACAN, DSEL, ETV2,MUM1L and BCORL1).
The most highly ranked SNPs associated with genes are
presented in Table 2. We identified 23 significantly mutated
genes between the epithelial and spindle cell areas of SS.
Most of these genes have not been previously reported in
SSs, and four genes, neuroguidin (NGDN), RAS protein ac-
tivator like 3 (RASAL3), KLHL34 and MUM1L1, have not
been previously linked to cancer. Only one gene (EP300)
has been reported in SS. NGDN is an EIF4E (MIM
133440)-binding protein that interacts with CPEB and
functions as a translational regulatory protein during the
development of the vertebrate nervous system [7]. RASAL3,
a member of the RAS signaling pathway, is located at
19p13.12 and contains 18 exons; it was identified in 2004
[8]. KLHL34 is a member of the Kelch-like (KLHL) gene
family, which encodes a group of proteins that generally
possess a BTB/POZ domain, a BACK domain and 5–6
Kelch motifs. KLHL genes are responsible for several Men-
delian diseases and have been associated with cancer. Fur-
ther investigation of this family of proteins will likely
provide valuable insights into basic biology and human dis-
ease [9]. The melanoma-associated antigen (mutated) 1-like
1 gene (MUM1L1) has four transcripts (splice variants).
This gene encodes a protein that contains a mutated
melanoma-associated antigen 1 domain. Proteins that con-
tain mutated antigens are probably expressed at high levels
in certain types of cancers. Multiple alternatively-spliced
variants, encoding the same protein, have been identified.
EP300 somatic mutations were significantly different be-
tween the epithelial and spindle cell components, and were
mainly located in the DNA-binding domain and the mu-
tated gene encoding histone H3 lysine acetyltransferases.
EP300 is a very important factor in the TGF-β signaling
pathway. SNPs located in genes with unknown functions or
without obvious importance to disease pathogenesis are
not discussed here.
Functional annotation of SS-associated variants
We analyzed 319 genes containing 336 SNPs significantly
associated with BSSs by SNP-chip analysis using the
WebGestalt functional clustering algorithm (Table 3). GO
analysis showed three aspects: biological processes
(biological regulation [43.9 %, 140/319] and metabolic
processes [41.1 %, 131/319]); cellular components (mem-
brane [45.8 %, 146/319] and nucleus [23.8 %, 76/319]);
molecular function (protein binding [46.4 %, 148/319] and
ion binding [26.3 %, 84/319]) (Fig. 2). SNPs were detected
in genes with potential relevance for epithelial and spindle
cell components of BSSs by Commons Pathway
Additional file 2 and Functional Enrichment Analysis
(WikiPathways Additional file 3 and KEGG pathways
Additional file 4), mainly in genes such as those involved
in the inflammatory response pathway, focal adhesion,
the TGF-β signaling pathway, ECM–receptor interac-
tions, phenylalanine metabolism and the JAK–STAT
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signaling pathway (Table 3). STRING network online
analysis was used for additional evaluation of the
enriched protein interaction network. The results
showed enrichment of functional categories including
focal adhesion, cytokine–cytokine receptor interac-
tions, the JAK–STAT signaling pathway, the ERB sig-
naling pathway, the cell cycle, adherens junctions and
the Wnt signaling pathway (Fig. 3).
Discussion
SSs harbor a chromosomal translocation t(X; 18)(p11.2;
q11.2), which produces the SS-specific fusion gene
SYT–SSX. Although the precise function of SYT–SSX
has not yet been studied, accumulating evidence sug-
gests its role in gene regulation via epigenetic mecha-
nisms, and the product of SYT–SSX target genes may
serve as biomarkers of SS [10, 11]. However, lack of
knowledge regarding the cell-of-origin of SS has ham-
pered identification of its targets [12]. The clinical out-
comes of SS are very poor and approximately 90 % of
patients die because of metastasis. Understanding the
process by which tumor cells destroy the basement
membrane, invade and metastasize is essential for the
advancement of SS treatment strategies and improve-
ment of survival. An intriguing observation in SS is that
the specific gene fusion (SYT–SSX1 vs. SYT–SSX2) cor-
relates strongly with the tumor phenotype (monophasic
vs. biphasic histology, as defined by the presence of glan-
dular epithelial differentiation with lumen formation),
and almost all BSS has been shown to harbor the SYT–
SSX1 fusion gene [13, 14]. Our results showed that most
cases are SYT–SSX1 fusion genes (8/11). Moreover,
Fig. 1 Genome-wide analysis of a total of 2,345,678 SNPs in epithelial and spindle components in 12 cases of biphasic synovial sarcomas. a Manhattan
plot showing negative log-transformed P-values of the case–control allele frequency significance on the y-axis. The color scale of the x-axis denotes
chromosome numbers. Gene names associated with individual dots indicate SNPs of greatest significance or with potential disease relevance.
b Mutation types of 343 SNPs meeting the established criterion for genome-wide significance (P < 0.05, chi square test)
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SYT–SSX fusion transcripts are found in both epithelial
and spindle cell areas of BSS [15].
The recent advances in high-throughput sequencing
technologies are rapidly becoming common practice. A
large amount of data are generated using these methods
and are becoming an important resource for deciphering
the genotype underlying a given phenotype in clinical
diagnosis, cancer research and molecular targeted ther-
apies for various cancers [4, 16]. Because of the relative
rarity of SS and its poor prognosis, it is not easy to col-
lect adequate numbers of fresh samples of SS for a
genome-wide association study. Therefore, it is very dif-
ficult to analyze subtle differences in pathogenesis and
clinical benefits on the basis of the histological type.
Therefore, future more in-depth studies should consider
these issues in the study design when FFPE tissue sam-
ples are used. Samples stored in diagnostic pathology ar-
chives represent an invaluable biobank for retrospective
clinical and molecular research. This is especially true in
the case of SS, which is a rare malignant tumor, and
FFPE tissue samples can alleviate or eliminate the need
for the tedious collection and storage of cryopreserved
clinical samples. It is more difficult to extract nucleic
acids from FFPE tissue because of the need to remove
the paraffin and to counteract covalent protein–DNA in-
teractions that result from the fixation process [17];
however, Schweiger et al. [18], who first reported NGS-
based analysis of DNA (DNA-Seq), had in fact used
FFPE samples in their study. Recently, Eliezer et al. [19]
also described an approach for generating high-quality
whole-exome sequencing (WES) data from archival
tumor material and validated WES data obtained from
FFPE tumor samples by using corresponding WES data
from frozen samples. The results showed that the ability
to detect base mutations with sufficient power was
equivalent regardless of whether frozen or FFPE tissue-
derived genomic DNA was used for WES. The power of
NGS (involving genomic SNP chips) for in-depth ana-
lysis of large numbers of short sequences potentially
makes this an ideal technology in the case of the frag-
mented nucleic acids that are usually extracted from
FFPE specimens [17]. Therefore, the development of re-
liable NGS-based methods for use with low-quality,
FFPE tissue-derived nucleic acids would enable the use
of samples from diagnostic pathology archives for high-
throughput profiling, thereby facilitating extensive
Table 2 Highly ranked SNPs associated with BSS
SNPs Name Chr MapInfo Alleles Location P valuea Gene(s) Mutation(s) Bp F_C
exm68141 1 70890007 [A/G] EXON 0.00904 CTH Missense_V166M, V134M,Silent 70890007 0.222
exm279897 2 238742929 [T/C] EXON 0.00904 RBM44 Missense_I1015T 238742929 0.222
exm2090870 5 145537108 [T/C] EXON 0.007661 LARS Missense_R308H 145537108 0.625
exm508367 5 177633872 [A/T] EXON 0.004678 HNRNPAB Missense_Y173F, 177633872 1
exm509539 5 178634672 [T/C] EXON 0.008741 ADAMTS2 Missense_V245I 178634672 0.583
exm514146 6 6167833 [A/T] EXON 0.003445 F13A1 Missense_L589Q 6167833 1
exm534246 6 32038079 [T/G] EXON 0.00572 TNXB Missense_F1701L 32038079 0.357
exm597614 7 975046 [C/G] EXON 0.001565 ADAP1 Missense_V60L 975046 1
exm648916 7 106515241 [T/C] EXON 0.007888 PIK3CG Missense_A795V 106515241 0.3
exm1042751 12 120580489 [T/C] EXON 0.00394 GCN1L1 Missense_R1884Q 120580489 0.333
exm1091040 14 23945331 [C/G] EXON 0.006545 NGDN Missense_V172L 23945331 0.444
exm1133291 14 105415882 [T/C] EXON 0.003676 AHNAK2 Missense_R1969Q 105415882 0.5
exm1186826 15 89401134 [T/C] EXON 0.008741 ACAN Missense_L1773P 89401134 0.5
exm1233625 16 30666358 [A/G] EXON 0.004862 PRR14 Missense_R356Q 30666358 0.556
exm1391659 18 65180127 [A/C] EXON 0.007982 DSEL Missense_L583F 65180127 0.5
exm1925094 19 15567000 [A/G] EXON 0.004898 RASAL3 Missense_C546R 15567000 0.313
exm1456897 19 36134208 [A/G] EXON 0.005775 ETV2 Missense_D90N 36134208 0.438
exm1593372 22 24179922 [G/C] EXON 0.006903 DERL3 Missense_F149L 24179922 0.389
exm1618561 22 46763654 [T/C] EXON 0.003973 CELSR1 Missense_Y2684C 46763654 0.444
exm1631314 X 21674603 [A/G] EXON 0.006928 KLHL34 Missense_A435V 21674603 0.667
exm1651515 X 105451287 [T/A] EXON 0.009534 MUM1L1 Missense_D621V 105451287 1
exm1656996 X 129149891 [A/G] EXON 0.004388 BCORL1 Missense_R1048Q 129149891 0.25
exm1611652 22 41546158 [A/C] EXON 0.004417 EP300 Missense_S106G 41546158 0.611
aChi-square test; F_C, the frequency of this variant in cases
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retrospective clinical studies. Our studies showed that
these two methods can be used to extract good-quality
DNA for detection with the exome SNP chip (call rate,
0.7526), using FFPE SS samples.
Morphologically, the most outstanding characteristic
of BSSs is the mixture of glandular solid epithelial sheets
or cystic papillary epithelial components and spindle
mesenchymal elements. The proportion of the epithelial
component varies widely. Some biphasic components
form glands with a highly atypical epithelium, and the
spindle cell component is composed of uniform mildly
hyperchromatic cells. The broad spectrum of histo-
pathological and molecular sarcoma subtypes, as well as
the clinical behavior of these tumors, is the reason for
the delay in clinical studies and preclinical discoveries.
Mertens et al. [20] reported that cytogenetic analysis has
not only provided important information on the patho-
genesis of soft-tissue tumors but, by identifying distinct
chromosomal rearrangements in different histopatho-
logical entities, has also come to serve as a valuable diag-
nostic tool. Therefore, to isolate pure tumor cell
populations, we demonstrate the efficacy of LCM coupled
with a cored tissue chip for the isolation of DNA
from epithelial and spindle components of SSs. LCM
is a well-established method for the isolation of cells
from biological mixtures, even when cells are found
in low abundance [21]. In our previous study [22], we
found significant differences between different histological
subtypes and epithelial–mesenchymal composition with
respect to the expression of the TGF-β1 pathway and
EMT-related proteins in SS. Our functional annotation of
SNP-chip data suggests that the differing morphologies of
BSSs indicate different genomic changes. The differential
mutations had 336 SNPs, which contained 319 genes
(including TGF-β1 pathway-related genes). For ex-
ample, exm1611770 in EP300, exm412589 in SPP1
and exm648916 in PIK3CG were found to be strongly
associated with BSSs. Therefore, these data perhaps
support the hypothesis that neoplastic EMT contrib-
utes to the transition between the spindle cell and
epithelial morphologies of SS.
Although our SNP analysis points to disease associa-
tions with many gene variants, the contribution of her-
editary factors to the SS phenotypes is currently
unknown. WebGestalt [6] is a suite of tools for func-
tional enrichment analysis in various biological contexts
(including GO Slim classification, directed acyclic graph
[DAG] structure, KEGG pathway, WikiPathways and
Pathway Commons pathway). The WebGestalt results
showed that the differential SNPs in genes for functional
enrichment were mainly related to the inflammatory re-
sponse pathway, adhesion, ECM–receptor interactions,
the TGF-β signaling pathway, the JAK–STAT signaling
pathway, phenylalanine metabolism, the intrinsic path-
way and fibrin formation. Moreover, those pathways that
closely correlated with tight junction genes served as a
Table 3 Functional enrichment analysis of top ranked SNPs
Different riched methods Related pathways of riched functional analysis P value Related genes of riched functional analysis
Wikipathways pathway Inflammatory Response Pathway 0.0013 IL4R, LAMC2, LAMA5, COL1A1
Focal Adhesion 0.0029 SPP1, COL1A1, COL5A1, EGF, TNXB, ROCK1, LAMC2,
PIK3CG, LAMA5
TGF Beta Signaling Pathway 0.0097 EP300, SPP1, JAK1, EGF
KEGG pathway ECM-receptor interaction 0.0004 GP9, SPP1, LAMA5, LAMC2, COL1A1, COL5A1, TNXB
Focal adhesion 0.0015 SPP1, FLT4, COL1A1, COL5A1, EGF, TNXB, ROCK1,
LAMC2, LAMA5, PIK3CG
Phenylalanine metabolism 0.0044 IL4I1, AOC2, ALDH3B2
Jak-STAT signaling pathway 0.0063 IFNE, EP300, IL4R, IL11RA, JAK1, PIK3CG, CBLB
Hematopoietic cell lineage 0.0085 CD1E, GP9, IL4R, IL11RA, CD22
Inositol phosphate metabolism 0.0111 PLCB4, PIK3C2B, PIK3CG, PIK3C2A
Pathway Commons pathway Intrinsic Pathway 0.0015 GP9, C1QBP, A2M, F13A1
Formation of Fibrin Clot (Clotting Cascade)- 0.0021 GP9, C1QBP, A2M, F13A1
Hemostasis 0.0054 TTN, OL1A1, A2M, EGF, F13A1, GP9, MAG, C1QBP
Platelet Activation 0.0054 GP9, COL1A1, A2M, EGF, F13A1
Exocytosis of Alpha granule 0.0050 GP9, A2M, EGF, F13A1
Platelet degranulation 0.0059 GP9, A2M, EGF, F13A1
Terminal pathway of complement 0.0037 C8G, C7
vWF interaction with collagen 0.0037 GP9, COL1A1
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signature for epithelial-like cancer cells or some inva-
sion- and metastasis-associated genes. Kohn et al. [23]
demonstrated that some highly correlated genes, includ-
ing genes involved in interactions at tight junctions, ad-
hesion junctions, desmosomes, transcription regulation
of cell–cell junction complexes, epithelial vesicle traffic
and epithelial Ca(+2) signaling, were implicated in epi-
thelial functions in NCI-60 human tumor cell lines and
the CCLE cell lines of the Broad Institute. Saito [24]
provided a good model for this epithelial differentiation,
which shows a possible mechanism for the aberrant
mesenchymal-to-epithelial transition (MET) of SS and
suggested that it would be better to consider it as an
epithelial-to-mesenchymal transition (EMT). Therefore,
these findings suggested that epithelial-like cancer cells or
aberrant MET were present by analyzing the regulation of
networks, whether carcinoma or sarcoma. These molecu-
lar signatures are not only important for appropriate
Fig. 2 GO output enrichment analysis of differential SNPs for target genes. Distribution of significant genes in gene function (molecular function)
and cell components (cellular component) categories, and those that participate in biological processes (in process)
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diagnosis but also contribute to the investigation of the
tumorigenic and metastatic mechanisms of cancer [25].
Our results also suggested that differing morphologies are
due to different genomic changes.
Conclusions
Clinical applications of genomic biomarkers have been
rapidly expanded and developed. Here, we performed a
genome-wide SNP analysis of the epithelial and spindle
cell components of BSSs. We found some significant
mutations in genes whose functional annotations
suggested involvement in cell adhesion, ECM–ECM
receptor interactions, the TGF-β signaling pathway
and cell junctions and signaling. These findings
closely correlate with our previous immunohisto-
chemical studies on SS, wherein TGF-β1 was found
to induce mesenchymal–epithelial transition and to
regulate biphasic differentiation. Such annotations
provide a framework and a new target for treatment
along with strategies for continued research on the
mechanism.
Availability of supporting data
The data discussed in this publication have been deposited
in LabArchives and are accessible through dataset DOI:
10.6070/H4Z31WP8 (http://www.labarchives.com/).
Additional files
Additional file 1: The summary of 336 differentiated data of SNP.
(XLSX 91 kb)
Additional file 2: Enrichment analysis of the Pathway Commons
Pathway of differentiated genes. (HTML 20 kb)
Additional file 3: Enrichment analysis of the Wikipathways Pathway
of differentiated genes. (HTML 24 kb)
Additional file 4: Enrichment analysis of the KEGG Pathway of
differentiated genes. (HTML 26 kb)
Fig. 3 STRING network analysis reveals a database of known and predicted protein interactions. The interactions include direct (physical) and indirect
(functional) associations. The network has been simplified for clear illustration of genes of interest. Stronger associations are represented by thicker
lines. The significant genes were mainly TP53, AKT1, SRC, EGF, EGFR, PIK3CG, EP300 and FYN, and enriched functional categories included focal adhesion,
cytokine–cytokine receptor interactions, the ERBB signaling pathway, the cell cycle, adherens junctions and the JAK–STAT signaling pathway
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Abbreviation
SS: Synovial sarcoma; BSS: Biphasic synovial sarcoma; SNP: Single nucleotide
polymorphism; NGDN: Neuroguidin; RASAL3: RAS protein activator like 3;
FFPE: Formalin-fixed, paraffin-embedded; LCM: Laser capture microdissection;
KLHL: Kelch-like; MUM1L1: Melanoma-associated antigen (mutated) 1-like 1
gene; GO: Gene ontology; KEGG: Kyoto encyclopedia of gene and genomes;
WES: Whole-exome sequencing; NGS: Next generation sequencing;
EMT: Epithelial-mesenchymal transition; MET: Mesenchymal-epithelial
transition.
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